Secret Sauce That Fuels DrNose

Hundreds of academic studies are available in the past 2 decades on how the breath can be used to detect various diseases including various types of cancers.

However, their primary focus is on capturing the breath of a person and sending it to an expensive gas chromatograph in a lab for analysis rather than for a real-time diagnosis.

Dr Nose is different. It has actually built a low cost, non-invasive device for self-use that can provide an early-stage diagnosis for multiple cancers and other chronic diseases in real-time.

There are two factors that constitute the “secret sauce” of DrNose.

1. The combination of sensors

Humans with certain diseases breathe out a variety of complex gaseous molecules. Dogs can smell these because their noses have around 300 million receptors in them. Humans are less sensitive but they too have around 6 million such receptors. DrNose is be able to diagnose multiple diseases using just 6 sensors.

What makes DrNose unique is knowing exactly which 6 sensors, in combination, are most efficacious for recognizing the presence of a disease and differentiating one from the other.

2. Multiple patented AI Algorithms

AI traditionally involves using very large quantities of data, tens or hundreds of thousands of data points, to extract patterns of information which can then be used for making a diagnostic decision. In reality, clinical trials tend to be small — only tens or, at best, a few hundred data points might be available.

DrNose requires only small datasets of 30 as its AI is based on “Intuitive AI”, a unique proven AI technology developed by its parent company, iOmniscient, which can achieve accurate results even with very small data sets.

Using Intuitive AI and the information from the 6 sensors, DrNose can generate a pattern which indicates exactly what a person may be suffering from.

This smell-based technology has already been deployed for over 20 years in industrial applications by iOmniscient and has been demonstrated to be both robust and reliable. Two clinical trials conducted for breast cancer (in Israel) and lung cancer (in Australia) have demonstrated achieving highly accurate results.

A commercial launch of the product for the consumer market is planned for the first half of 2025.

This is a preventive diagnostic tool. By detecting diseases early, they can be treated with less aggressive treatment ensuring patients can be treated earlier, recover faster and live longer.